On September 10, 2026 OncoHost, a technology company transforming precision oncology through proteomics-based biomarker development, reported its acceptance to present a scientific poster at the 2026 World Conference on Lung Cancer (WCLC), taking place September 12–15, 2026, in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC," evaluates whether PROphetNSCLC maintains its predictive performance when blood samples are collected beyond the traditional pre-treatment time point.

PROphetNSCLC is a plasma proteomics-based test designed to guide immune checkpoint inhibitor (ICI) treatment decision-making in advanced non-small cell lung cancer (NSCLC). While PROphetNSCLC was developed using samples collected prior to initiation of ICI treatment, real-world clinical workflows may not always allow for baseline blood collection. The study therefore assessed the stability of the plasma proteome and the concordance of PROphetNSCLC result in different sampling time points.

"The PROphet plasma proteomic assay has proven clinical utility as a baseline in treatment naïve patients, but in practice some patients don’t have pre-treatment samples" said Dr. David Gandara, Medical Oncologist & clinical-translational researcher in lung cancer, Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center, Clinical Advisor at OncoHost and co-author of the study. "These new data that PROphet results remain stable even after a patient begins chemotherapy or immunotherapy reinforce the reliability and clinical applicability of the assay".

"Immunotherapy is today the cornerstone of treatment for NSCLC patients without an oncogenic driving abnormality", added Fred Hirsch, MD, PhD, FASCO, Professor of Medicine & Pathology, Medical Oncologist, Clinical Advisor at OncoHost and co-author of the study. "The PROphet blood-based assay has demonstrated in several studies it can predict which patients who will benefit from immunotherapy with or without chemotherapy or not. The presented study shows the predictive stability of the test even if it is sampled during treatment, which makes the test very usable in the real-world setting".

The analysis included plasma samples collected from patients with advanced NSCLC receiving ICI-based therapies at three time points: prior to treatment; following one cycle of chemotherapy but before initiation of ICI therapy; and following one cycle of ICI-based treatment. Proteomic profiling measured 7,289 proteins, while investigators evaluated changes across the plasma proteome, preservation of Resistance Associated Protein (RAP; the PROphetNSCLC model proteins) expression, and the consistency of PROphet classification.

Results demonstrated substantial preservation of the biological signal underlying PROphetNSCLC despite treatment initiation. Among matched samples collected at baseline and following one cycle of chemotherapy, only 20 of the 7,289 measured proteins were differentially expressed, with none belonging to the 388 RAPs used by PROphet. Greater proteomic changes were observed following one cycle of ICI-based treatment, with 888 differentially expressed proteins, including 81 RAPs. Despite these changes, more than 73% of RAPs remained strongly correlated between matched samples across both longitudinal comparisons.

Comparison between the plasma proteome at baseline and after 1 chemotherapy or ICI-based cycle showed that more than 73% of the RAPs remained strongly correlated between matched samples. In concordance with the RAP preservation, PROphet classification demonstrated high consistency between matched samples, reaching 80% following chemotherapy and 69% following one cycle of ICI-based treatment, with no significant systematic bias compared with baseline classification. Importantly, PROphet maintained significant separation in overall survival between PROphet-POSITIVE and PROphet-NEGATIVE patients following one cycle of ICI-based treatment (HR=0.54, p=0.009).

"These findings represent an important step in expanding the real-world clinical utility of PROphetNSCLC," said Ofer Sharon, M.D., CEO of OncoHost. "Our goal is to ensure that more patients can benefit from precision treatment guidance, even when the realities of clinical care may require treatment to begin before all biomarker results are available. Demonstrating that PROphet maintains its predictive performance following one cycle of chemotherapy broadens the patient population for whom the test may be relevant and reinforces our commitment to delivering precision oncology solutions that integrate seamlessly into real-world clinical practice."

Poster Presentation Details
Title: PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC
Poster Board #: P2.188
Presenters: David R. Gandara, M.D. & Fred Hirsch, M.D., co-authors of the study
Date & Time: 14/09/26 10:30-12:00 PM KST.

(Press release, OncoHost, SEP 10, 2026, View Source [SID1234670738])

On September 10, 2026 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported the presentation of an abstract1 at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq technology in the detection of early-stage I solid cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Andrew Retter, Medical Consultant, Volition, said:

"We were delighted to be selected to present in the main auditorium at this prestigious conference.

"From a clinical perspective, the proof of concept and early blinded validation results reported are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 healthy controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional healthy controls2.

"We also subsequently reported data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and the results are likewise very promising; the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy3.

"For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.

"We also believe that Capture-Seq has the potential to play a role in cancer management, including but not limited to, Minimal Residual Disease detection and treatment monitoring, either alone or potentially in combination with other technologies too."

Dr Jake Micallef, Chief Scientific Officer, Volition added:

"This new method isolated CTCF-protected plasma ctDNA from background cell free DNA bound to nucleosomes2. Analysis of the isolated CTCF-protected ctDNA produced sequencing data sets for blood samples from early stage cancer patients that were absent from blood samples of healthy control subjects.

"These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers. Capture-Seq shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease (MRD).

"We are fast-tracking the development of Capture-Seq: conducting further studies, including competing conditions and working with oncology Key Opinion Leaders.

"Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."

Details:

ESMO MAP brings together leading experts in oncology, molecular diagnostics, and precision medicine for two days of high-level exchange, collaboration, and innovation.

10th September, 14:55pm, Main Auditorium, London Business Design Centre

Conference abstract
Pamart, D., et al. Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy. Clin Epigenet (2026). View Source
Data on File : Volition TAM Model

(Press release, VolitionRX, SEP 10, 2026, View Source [SID1234670737])

On September 10, 2026 Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, reported that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit’s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x’s oncology-focused clinical research studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10x Genomics is a leader in single cell and spatial biology, with its technologies cited in more than 10,000 research publications and enabling discoveries across oncology, immunology, neuroscience and other fields.

The work brings together molecular insights generated using 10x’s Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analyzing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to the underlying biology of tumors and identify biomarkers associated with treatment response and resistance.

"10x Genomics has built powerful tools for understanding the molecular organization of tissue," said Brandon Suh, CEO of Lunit. "Lunit SCOPE IO adds the ability to analyze the full H&E landscape at scale. Together, we believe these technologies can help researchers connect deep molecular insight with the tissue patterns that pathologists recognize every day."

"Spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment," said Roman Yelensky, Vice President, Clinical Applications of 10x Genomics. "By combining that molecular depth with Lunit’s AI-based analysis of the same H&E images pathologists work with every day, we can give researchers a more complete view of the tumor to accelerate the discovery of biomarkers that could inform treatment strategies and enable potential future diagnostic development."

The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x’s broader effort to explore potential future diagnostic applications of spatial technologies in oncology.

Lunit SCOPE IO uses deep learning to analyze whole-slide H&E pathology images and characterize tissue features including tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other features of the tumor microenvironment. Used alongside 10x’s spatial technologies, these analyses provide additional tissue context that complements molecular profiling in oncology clinical research.

(Press release, Lunit, SEP 10, 2026, View Source [SID1234670736])

On September 10, 2026 U.S. Food and Drug Administration reported it has granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The experimental CAR T-cell therapy was developed by researchers at CU Anschutz and will be manufactured at the campus’ Gates Biomanufacturing Facility. The cells are designed to attack two targets associated with cancer: B7-H3, a protein found on most colorectal tumors, and IL-8, a protein that helps promote tumor growth, inflammation and the spread of cancer.

If successful, the approach could eventually be tested against other cancers in which these pathways play a role, including some breast, lung and ovarian cancers.

"This is a very different way of thinking about how we treat cancer," said Michael Verneris, MD, professor of pediatric oncology at CU Anschutz and program co-leader of Tumor-Host Interactions at the CU Anschutz Cancer Center. "We wanted to find targets that are present across many different cancers rather than developing a therapy that would only apply to a small number of patients."

Christopher Lieu, MD, professor of medical oncology at CU Anschutz and associate director of clinical research at the CU Anschutz Cancer Center, is leading the trial.

A two-pronged approach

CAR T-cell therapy involves collecting a patient’s T cells, a type of immune cell, and genetically modifying them so they can recognize and attack cancer. The engineered cells are then grown in large numbers and returned to the patient.

CAR T-cell therapies have produced remarkable results in some blood cancers, including leukemia and lymphoma. But developing CAR T-cell treatments for solid tumors such as colorectal cancer has proved much more difficult.

One challenge is finding a target that is abundant on cancer cells but limited on healthy tissue.

B7-H3 is attractive because it is found on many colorectal cancers. Researchers at several institutions are investigating B7-H3 as a potential cancer target, but the CU Anschutz therapy takes an additional step by simultaneously targeting IL-8, which is part of a pathway that can help tumors grow and spread.

The researchers hope the combination will give the engineered cells a better chance of overcoming the defenses of solid tumors.

"Chemotherapy extends survival and helps cure people," Lieu said. "At the same time, it’s like dropping an unguided bomb on a disease. Maybe you hit your target, but you are going to do a lot of collateral damage."

He’s hoping this therapy, which has proven effective in animal models, will produce longer results. Not two months or four months but years.

"Immunotherapy gives us the opportunity to direct the immune system toward the cancer and potentially produce a much more durable response," he said.

An urgent need for new treatments

Colorectal cancer is increasingly affecting younger adults. Rates of colorectal cancer among people under 45 have risen substantially over the past several decades, while researchers continue to investigate the reasons behind the trend.

For patients with advanced colorectal cancer, treatment options become increasingly limited when standard therapies stop working.

"Given the number of patients we are seeing, we need new approaches," Lieu said.

Currently, only a small percentage of patients with colorectal and other gastrointestinal cancers are eligible for certain forms of immunotherapy because those treatments require specific tumor biomarkers. Because B7-H3 is present in a much larger proportion of colorectal cancers, the researchers hope their approach could ultimately be applicable to more patients.

But the first step is determining whether the therapy is safe and whether it can effectively attack cancer in people.

From laboratory to clinical trial

The trial highlights the innate advantages of CU Anschutz – home to a university, Children’s Hospital Colorado, UCHealth University of Colorado Hospital and the Gates Biomanufacturing Facility all within easy walking distance of each other. This unique positioning allows researchers to seamlessly move their work from an idea to a laboratory experiment to a clinical trial.

"The whole spectrum is right here," Verneris said. "If we didn’t have the Gates Institute, we wouldn’t be able to make our own cells. This could have remained an interesting idea. Instead, it has become a clinical trial that could have a real impact on patients."

Philanthropic support has played an important role in advancing the therapy toward clinical testing.

"These trials cost a lot of money," Verneris said. "Private philanthropy is what makes it possible to take an idea like this and move it into patients. We are incredibly grateful to the donors who have helped make this possible."

The trial is expected to begin in December.

(Press release, University of Colorado-AMC, SEP 10, 2026, https://www.prnewswire.com/news-releases/fda-clears-cu-anschutz-clinical-trial-using-engineered-immune-cells-to-fight-colorectal-cancer-302875707.html [SID1234670735])

On September 10, 2026 Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, reported its participation in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

September 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
10:30 a.m. ET – fireside chat

September 23, 2026
Stifel 2026 Virtual Immunology and Inflammation Forum
12:30 p.m. ET – fireside chat

A simultaneous webcast of both events will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

(Press release, Nkarta, SEP 10, 2026, View Source [SID1234670733])